
Comparing DASL-HiCaP Trial with ENZARAD and STAMPEDE Trials and Discussion of Agent Choice
The moderator asks one of the panelists to compare the DASL-HiCaP trial with the STAMPEDE and ENZARAD trials.
The moderator asks one of the panelists to compare the DASL-HiCaP trial with the STAMPEDE and ENZARAD trials. The panelist provides their takeaways from the trials. The panel also discusses patients who are positive only on PSMA PET, and one panelist warns against the risk of over-staging patients based on an example such as a questionable lymph node, since treatment can also bring side effects. One panelist adds onto the conversation surrounding side effects and proceeds to highlight the differences in safety and tolerability amongst the treatments and how that affects his choice of agent in clinic for his patients. The panelist adds that agent choice will rest on safety, tolerability, and provider experience, in which he has seen darolutamide be well-tolerated in his clinic.
Related to this article








